Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05962437

Self-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia

Introduction: Fibromyalgia (FM) is a prevalent syndrome that lacks curative treatment, imposing high healthcare and societal costs. The SMART-FM-Spain study investigates the effectiveness, physiological effects, and cost-utility of a self-guided digital intervention (STANZA-Spain) based on Acceptance and Commitment Therapy (ACT) for patients with FM.

Methodology: Six-month, 3-arm randomized controlled trial (RCT) A total of 360 adult individuals meeting the 2016 American College of Rheumatology (ACR) criteria for FM will be recruited at Vall d'Hebron University Hospital (Barcelona, Spain), The Rheumatology Service of the Parc Sanitari Sant Joan de Déu (Sant Boi, Spain), The San Juan de Dios Hospital of Palma (Palma de Mallorca, Spain) and The San Juan de Dios Hospital of Aljarafe (Sevilla, Spain). They will be randomly allocated to one of the three study arms: Treatment as usual (TAU) plus STANZA-Spain, TAU plus digital symptom tracking (FibroST), or TAU. Participants will be assessed at baseline, post-treatment, and 6 month-follow-up. The primary outcome will be functional impairment, as measured by the FIQR; secondary outcomes will include patient impression of change, depression-anxiety-stress, and pain catastrophizing, among others constructs relevant to FM. Effectiveness and cost-utility analysis from a societal perspective will be computed, whereas ACT-related constructs, such as psychological flexibility, will be assessed to identify processes of change that will be analyzed with path analyses. Immune-inflamatory biomarkers will be assessed at baseline and post-treatment in 30-40 participants of each study arm. Additionally, a qualitative substudy using focus group thematic analysis will be conducted to deepen the understanding of STANZA app user experiences.

Discussion: This study might represent a significant advancement in the management of FM in Spanish-speaking patients with FM, by examining the effectiveness, physiological effects, and cost-utility of a smartphone-based digital therapeutic with demonstrated empirical support in the United States of America.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Vall d'Hebrón, Barcelona, Spain

Loading trial locations.

About this study

Main goals of the SMART-FM-SP study The main objectives of this RCT are: To analyze the effectiveness of adding Acceptance and Commitment Therapy via app (STANZA) compared to an active control arm (Fibro Symptom Tracker app -FibroST-) to the treatment as usual (TAU) for patients diagnosed of fibromyalgia; To examine the cost-utility of STANZA from healthcare and societal perspectives; To measure a set of immune-inflmmatory biomarkers alongside the RCT in order to know the physiological underpinnings of the digital intervention STANZA and to identify potential predictors of treatment response.

Smart-FM-SP is a 6-months RCT with three arms: TAU, TAU+STANZA and TAU+FibroST. Therefore, patients in three arms will receive TAU, and FibroACT and FibroST will be complementary treatments to the standard one provided in the public Health System.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fibromyalgia diagnosis according to the 2016 ACR criteria
  • Fibromyalgia Impact Questionnaire Revised (FIQR) total score within the range of 35-80 at baseline.
  • Willing to maintain their current pain treatment throughout the study.
  • Having a smartphone (iOS 12 or higher or Android OS 8 or higher).
  • Proficient understanding of Spanish.

Exclusion criteria

  • Presence of cognitive impairment according to clinical records.
  • Diagnosis of severe medical or mental disorders such as cancer, psychotic disorder, and drug abuse according to medical records.
  • Patients at risk of suicide.
  • Being pregnant or planning a pregnancy during the study period, or currently breastfeeding.
  • Participation in other clinical trials during the study or within the previous 12 months.
  • Unable to use a smartphone.

Exclusion criteria

for biomarkers substudy (30-50 patients in each study arm):

  • Male sex
  • Comorbid rheumatologic disorders such as lupus or severe organ dysfunction.
  • History of fever (> 38ºC) or infection within the last 2 weeks.
  • Vaccination within the last 4 weeks.
  • Recent physical trauma
  • Needle phobia.
  • Consumption of more than 8 units of caffeine per day.
  • Smoking more than 5 cigarettes per day.
  • Current use of oral or topical corticosteroids.
  • Current use of anti-cytokine biologic medications.
  • Current use of oral contraceptives.

Treatment and study plan

Self-guided digital Acceptance and Commitment Therapy

Device

Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks with minimal involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.

FM symptom tracking app (FM-ST)

Device

Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.

Treatment as Usual (TAU)

Behavioral

Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)

Primary outcomes

  1. Fibromyalgia Impact Questionnaire Revised (FIQR)

    Time frame: Through study completion, an average of 6 months

    The FIQR includes 21 items that are answered on a 0-10 numerical scale in which higher scores indicate greater functional impairment. The FIQR assesses the impact of FM symptoms over the past 7 days. The questionnaire consists of items that cover three domains: physical impairment, overall impact, and symptom severity. These items inquire about various aspects such as pain, energy levels, stiffness, sleep quality, depression, memory problems, anxiety, sensitivity to touch, balance issues, and heightened sensitivity to noises, lights, smells, or temperatures. The total FIQR score is calculated by summing the scores of the three subscales, resulting in a range of 0 to 100. Higher scores indicate a greater level of impairment. The Spanish version of the FIQR has an excellent internal consistency (α = 0.91-0.95)

Secondary outcomes

  1. The Patient Global Impression of Change (PGIC) and the Pain Specific Impression of Change (PSIC)

    Time frame: At 3 and 6-months follow-up

    This instrument is an indicator of meaningful clinical change in treatments for chronic pain. The PGIC is one item (on a 7-point numerical scale, from 1 = 'Much better' to 7 = 'Much worse') referred to the participants' perception of global improvement due to treatment. It has undergone validation in the context of psychologically-based treatments for chronic pain. Additionally, the PSIC evaluates (also on a 7-point Likert scale) changes in specific domains, including physical and social functioning, work-related activities, mood, and pain. Both the PGIC & PSIC scales will be completed by participants assigned to STANZA and FM-ST treatments.

  2. The Depression Anxiety Stress Scales-21 (DASS-21)

    Time frame: Through study completion, an average of 6 months

    It discriminates between features of depression, anxiety and stress in clinical and non-clinical samples. Responders are required to indicate the presence of several symptoms over the previous week. Each item is scored from 0 (´Did not apply to me at all over the last week') to 3 ('applied to me very much or most of the time over the past week'). There are 7 items on each of the three subscales: depression, anxiety and stress. Therefore, total scores in each scale can range from 0 to 21, with higher scores indicating more severe levels of depression, anxiety and stress. The Spanish version has excellent psychometric properties.

  3. The Multidimensional Inventory of Subjective Cognitive Impairment (MISCI)

    Time frame: Through study completion, an average of 6 months

    It is a 10-item self-report measure of subjective cognitive dysfunction in FM during the last week. Each item is scored from 1 ('Not at all/Never') to 5 ('Very much/Always') and the total score ranges from 10 to 50. Lower scores indicate higher cognitive dysfunction. The MISCI was developed through classical test theory and item response theory from cognitive functioning item banks developed within the Patient Reported Outcomes Measurement Information System (PROMIS). The Spanish version of the MISCI has excellent internal reliability (α = 0.91)

  4. The Pain Catastrophising Scale (PCS)

    Time frame: Through study completion, an average of 6 months

    Scale of 13 items comprising three dimensions: rumination over pain, magnification of pain and helplessness in the face of pain symptoms. The PCS total score and subscale scores are computed as the sum of ratings for each item.

    This study uses the total score, which can vary from 0 to 52 with higher scores indicating greater pain catastrophising.

Other outcomes

  1. Psychological Inflexibility in Pain Scale (PIPS)

    Time frame: Through study completion, an average of 6 months.

    12-item scale that assesses psychological inflexibility in patients with pain and includes two factors: avoidance and cognitive fusion with pain. For this study, only the total score is used; it ranges from 12 to 84, with higher scores indicating higher level of psychological inflexibility.

  2. Psy-Flex

    Time frame: Through study completion, an average of 6 months.

    This brief 6-item questionnaire assesses psychological flexibility during the past week. It is based on the Acceptance and Commitment Therapy model (ACT; Hayes et al.), which identifies six core dimensions of psychological flexibility: acceptance, cognitive defusion, contact with the present moment, self-as-context, values, and committed action. Each item is answered on a 5-point Likert scale, ranging from 1 ("very rarely") to 5 ("very frequently"). The total score is obtained by summing the responses of the six items; higher scores reflect a higher level of psychological flexibility.

  3. Chronic Pain Acceptance Questionnaire (CPAQ-8)

    Time frame: Through study completion, an average of 6 months.

    This scale is composed of 12 items and it measures measure psychological inflexibility in people with chronic pain. It consists of two subscales: avoidance and cognitive fusion in relation to pain. Each item is answered on a 7-point Likert scale, where 1 means "never true" and 7 "always true". The total score ranges between 12 and 84, and higher scores indicate a greater degree of psychological inflexibility.

  4. EuroQoL (EQ-5D-5L)

    Time frame: Through study completion, an average of 6 months

    Instrument for evaluating health-related quality of life. The EQ-5D-5L scores will be used to calculate the Quality-Adjusted Life Years (QALYs) for the cost-utility analysis

  5. Client Service Receipt Inventory (CSRI)

    Time frame: Baseline and 6- months follow-up

    The version used in this study is designed to retrospectively collect information on the use of health and social services during the previous six months. This instrument does not provide total or sub-scale scores, only collects information about use of services and medication consumption.

  6. mHealth App Usability Questionnaire (MAUQ)

    Time frame: At 3 and 6-months follow-up

    It consists of 21 items grouped into three dimensions: usability and satisfaction, system information arrangement, and efficiency. Responses are recorded on a 7-point Likert scale, ranging from 1 ("strongly agree") to 7 ("strongly disagree"). Values closer to 1 indicate higher usability of the application. For this study, only the usability and satisfaction dimension will be used.

  7. Adverse effects of therapies

    Time frame: Through study completion, an average of 6 months

    Qualitative ad hoc measure to check the presence of negative effects of the therapies

  8. Patient Health Questionnaire (PHQ-9)

    Time frame: Baseline

    The PHQ-9 is a 9-item questionnaire that assesses the presence and severity of depressive symptoms over the last two weeks. Each item is scored from 0 ("not at all") to 3 ("nearly every day"), resulting in a total score ranging from 0 to 27. For this study, only item 9 will be used, which evaluates the presence of thoughts related to death or suicidal ideation/intent.

  9. Socio-demographic and clinical questionnaire

    Time frame: Baseline

    Gender, date of birth, marital status, living arrangements, educational level, employment status, and years lived with fibromyalgia

  10. Immune biomarkers

    Time frame: Baseline and 3-months follow-up

    Serum levels of IL-4, IL-6, CXCL8, IL-10, IL-17A, brain-derived neurotrophic factor (BDNF), and high sensitivity C-reactive protein (hs-CRP)

  11. Focus Group Discussions (FGD)

    Time frame: 3-month post-intervention

    Participants' experience will be recorded during the focus group discussion, guided by the semi-structured questionnaire.

Study contacts

Contact information is provided by the study sponsor or research team.

Jaime Navarrete, PhD

CONTACT

[email protected]

+34936406350 ext. 2543

Paula Ponce López, Msc

CONTACT

[email protected]

+34678758047

Sponsors and collaborators

Lead sponsor

Fundació Sant Joan de Déu

Other

Collaborators

  • Swing Therapeutics, Inc.

Registry information

Official study title

Three-arm Randomized Controlled Trial Investigating the Effectiveness, Cost-utility, and Physiological Effects of the Spanish Version of STANZA®: A Self-guided Digital Acceptance and Commitment Therapy (ACT) for Fibromyalgia

Acronym: SMART-FM-SP

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jul 27, 2023
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.